WATCH LIVE: Kennedy and Collins announce new PTSD research investment

Original Media · 24m · English · YouTube · PBS NewsHour

TLDR

The U.S. Department of Health and Human Services, VA, ARPA-H, CMS, FDA, and NIMH announced coordinated investments to accelerate research on psychedelic treatments for PTSD and serious mental illness, with a focus on veterans. Key commitments include up to $4.9 million through ARPA-H for ibogaine development with Mark Cuban's Cost Plus Drugs, data sharing from Beyond's 3,000-patient clinic in Mexico, a $20 million NIMH network for rapid-acting psychotropics like ketamine and psilocybin, and FDA requests for public input on trial design. All data will be open-sourced, and pricing aims to match generic drugs if approved.

For you

PRO members can sign in and request more information — or their own version of this digest, tuned to what they care about.

Sign in to unlock

Surprising Insights

•

The government is requiring open-sourcing of all clinical trial data from awardees, including negative findings, which contradicts standard pharmaceutical industry practice of keeping trial data proprietary.

•

Mark Cuban's Cost Plus Drugs agreed to transparent Cost Plus contracts and open-sourcing manufacturing processes, aiming for generic-drug pricing if ibogaine is approved — a rare commitment to affordability during the development phase.

•

Beyond's Mexican clinic data from 3,000+ patients and 6,000+ doses is being used to accelerate U.S. trials, despite the FDA not recognizing foreign clinical data as a substitute for U.S. gold-standard trials.

Key takeaways

•

ARPA-H is funding Cost Plus Drugs to develop U.S.-based manufacturing and regulatory pathways for single-molecule ibogaine hydrochloride, using transparent Cost Plus contracts and open-sourcing all data to accelerate future clinical trials for PTSD.

•

Beyond, a Texas-based company operating a hospital in Mexico, has treated over 3,000 patients with 6,000 ibogaine doses and agreed to transfer its evidence-driven, physician-led clinical data to ARPA-H to dramatically accelerate the clinical trial process.

•

NIMH launched a $20 million funding opportunity (split across two fiscal years) to establish a research network studying rapid-acting psychotropic drugs including ketamine, esketamine, and psilocybin for serious mental illness, with awards expected in summer 2027.

•

FDA opened a request for information due November 20th seeking public input on early-phase ibogaine study design, including dose selection, eligibility criteria, safety monitoring, and stopping rules, which will inform trial review.

•

All awardees must share research data openly while protecting patient privacy — a departure from typical proprietary trial data — so negative findings and evidence of harm can prevent duplicated failures and inform development decisions.

•

CMS is exploring Medicare coverage pathways including wrap-around support for clinicians administering these treatments in clinical trials, and potential state demonstrations to build evidence for future coverage decisions.

•

The HHS-VA partnership signed in July 2025 breaks down silos to combine ARPA-H's product development capabilities with VA's integrated health system and clinical expertise, aiming for FDA-authorized trials with independent ethics review and strict monitoring.

•

Officials emphasized these investments fund development groundwork only — not patient treatment or human subject research — and do not constitute FDA approval or a conclusion that ibogaine is safe or effective for PTSD.

Notable quotes

“We're going to open source every aspect of this system so that we know that we're getting the best prices that we could possibly get, and they'll be on the same commissary with the kind of deals that we get from generic companies.”

▸ Notable quotes · 1:50

“We are not taking shortcuts. Our clinical research will move forward with FDA authorization, independent ethics review, and strict patient monitoring protocols.”

▸ Notable quotes · 11:25

“Most of the time that these trials take place, the information is proprietary, and the drug companies do not share it. But in these trials, again, to accelerate the process and public access to these interventions, we are requiring the companies to open source all of their data.”

▸ Notable quotes · 6:09

“Negative findings can prevent researchers from repeating unsuccessful approaches. Evidence of harm can change development decisions. We need those results as much as we need evidence of benefit.”

▸ Notable quotes · 6:48

“If this work succeeds and the medicine earns FDA approval, our pricing will be comparable to that of other generic drugs, thanks to the agreement that we've made with Mark Cuban.”

▸ Notable quotes · 7:08

“Our system today is built on one-size-fits-all trial-and-error therapeutics. We deserve better. Our veterans deserve better.”

▸ Notable quotes · 13:22

Chapters

•

0:00 — Opening Announcements: Secretary Kennedy announces executive order implementation with two major investments: ARPA-H funding for ibogaine development with Cost Plus Drugs, and data transfer from Beyond's Mexican clinic to accelerate trials.

•

9:21 — VA Partnership and Safety Framework: Andrew Gratison outlines VA's three priorities — veteran safety, best-in-class research, and timely care delivery — and emphasizes the HHS-VA partnership to study ibogaine responsibly with FDA authorization and ethics review.

•

12:51 — ARPA-H Strategy and Data Acquisition: Dr. Rafid Fadul details ARPA-H's approach: acquiring Beyond's international patient data, funding multiple IND efforts through Cost Plus Drugs, and pursuing breakthroughs for 14 million Americans with severe mental illness.

•

14:58 — CMS Coverage and Access Planning: Dr. Mehmet Oz discusses CMS's role in ensuring treatments are reasonable and necessary for 165 million federally insured Americans, exploring wrap-around coverage for clinical trial participants and state demonstrations.

•

18:11 — FDA Regulatory Commitment: Acting Commissioner Kyle Diamantes affirms FDA's open-minded evaluation of innovative therapies, commitment to safety and efficacy, and coordination under the HHS-FDA-VA memorandum of understanding.

•

19:38 — NIMH Rapid-Acting Psychotropics Network: Dr. Andrea Beckel-Michner announces NIMH's $20 million investment for a research network on rapid-acting psychotropics including ketamine, esketamine, and psilocybin, with a data coordination center and focus on real-world trial settings.

•

22:02 — Q&A on Timeline: Reporter asks about timeline for treatment availability; ARPA-H representative states adherence to FDA policies but record speed through parallel IND filings and Beyond's data procurement.

Speakers

•

Secretary Kennedy — HHS Secretary

•

Andrew Gratison — VA Representative

•

Dr. Rafid Fadul — ARPA-H Chief Medical Officer

•

Dr. Mehmet Oz — CMS Administrator

•

Kyle Diamantes — FDA Acting Commissioner

•

Dr. Andrea Beckel-Michner — NIMH Acting Director

⋮